NurExone Biologic
Highly Engaged Employees
Highly Engaged EmployeesBusiness Services · Israel · 11-50 Employees
View Company Info for Free
Overview
Headquarters
IsraelWebsite
www.nurexone.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About NurExone Biologic
NurExone is a biotechnology company focused on developing innovative exosome-based therapies for acute spinal cord injury and glaucoma, addressing significant unmet medical needs in these areas. Their ExoTherapy platform utilizes nanosized extracellular vesicles to deliver therapeutic compounds, promoting regeneration and recovery in damaged tissues. With a commitment to minimal invasiveness and effective drug delivery, NurExone aims to revolutionize treatment options for patients. The company is positioned to tap into multi-billion dollar global markets, with a dedicated team and proprietary technology driving their research and development efforts.Explore more
NurExone Biologic Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is NurExone Biologic your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if NurExone Biologic is spiking on competitors!
Funding: Get notified immidiatlly once NurExone Biologic has new funding data
Check if NurExone Biologic has recently received funding, and reach out quickly before it becomes old news!
Click to see if NurExone Biologic had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when NurExone Biologic launches new products
NurExone Biologic, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on NurExone Biologic recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at NurExone Biologic
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Company Profile Activity
Activity Insights
NurExone Biologic is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
NurExone Biologic is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about NurExone Biologic.
NurExone Biologic financials insights
Gather financial insights about NurExone Biologic, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2025
Private Equity
$148K
2026
Private Equity
$280K
NurExone Biologic Tech Stack
A closer look at the technologies used by NurExone Biologic
See more technologies
Most Recent Scoops
Earnings
Earnings, Finance
Earnings
Earnings, Finance
Earnings
Earnings, Finance
Funding
Funding
Left Company
Executive Move
Executive Moves, Left Company
NurExone Biologic News & Media
Exo-Top, NurExone’s wholly owned U.S. Subsidiary, Enters Into Binding MOU For Naïve Exosome Distribution in Mexico
TORONTO, Ontario and HAIFA, Israel, June 25, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies, is pleased to announce today that its wholly owned U.S. subsidiary, Exo-Top Inc. (“Exo-Top”), has entered into a binding memorandum of understanding (the “MOU”) setting out the principal commercial terms for a proposed definitive distribution agreement (the “DeEXCLUSIVE: NurExone Targets Mexico Wellness Market With Exosome Supply Agreement (UPDATED)
Editor’s Note: The story has been updated to correct NurExone’s headquarters Canada and Israel-based biopharma company NurExone Biologic Inc. (OTCQB:NRXBF) on Wednesday said its wholly owned U.S. subsidiary, Exo-Top Inc., entered into a binding memorandum of understanding with ExoLyra LLC outlining terms for a proposed exclusive distribution agreement in Mexico for Exo-Top’s naïve mesenchymal stem cell (MSC)-derived exosome products. The companies intend to finalize a definitive agreement withinNurExone Announces First Quarter 2026 Financial Results and Provides Corporate Update
TORONTO, Ontario and HAIFA, Israel, June 01, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies, is pleased to announce its financial results for the first quarter ended March 31, 2026, and to provide a corporate update on recent activities and upcoming milestones.NurExone Receives Notice of Patent Grant in South Korea Covering ExoPTEN Technology
Expands intellectual property protection in a strategically important market for the Company’s lead exosome-based therapy targeting nerve repair and functional recovery Expands intellectual property protection in a strategically important market for the Company’s lead exosome-based therapy targeting nerve repair and functional recovery
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding NurExone Biologic
Sign Up For FreeTo access detailed company insights
NurExone is a biotechnology company focused on developing innovative exosome-based therapies for acute spinal cord injury and glaucoma, addressing significant unmet medical needs in these areas. Their ExoTherapy platform utilizes nanosized extracellular vesicles to deliver therapeutic compounds, promoting regeneration and recovery in damaged tissue... Read More
